Clinical Trial Update: Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a fixed-ratio combination of insulin glargine and lixisenatide versus basal insulin glargine in type 2 diabetes patients not adequately …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• insulin glargine/lixisenatide fixed-ratio combination (insulin glargine, lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED